BR0211905A - Dialdeìdos de rapamicina - Google Patents

Dialdeìdos de rapamicina

Info

Publication number
BR0211905A
BR0211905A BR0211905-6A BR0211905A BR0211905A BR 0211905 A BR0211905 A BR 0211905A BR 0211905 A BR0211905 A BR 0211905A BR 0211905 A BR0211905 A BR 0211905A
Authority
BR
Brazil
Prior art keywords
dialdehydes
rapamycin dialdehydes
rapamycin
dialdeids
rapamicin
Prior art date
Application number
BR0211905-6A
Other languages
English (en)
Inventor
Tianmin Zhu
Mahdi Bakir Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0211905A publication Critical patent/BR0211905A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DIALDEìDOS DE RAPAMICINA". A invenção refere-se a dialdeídos de rapamicina não-imunos-supressores, que são úteis como agentes neurotróficos, para o tratamento de tumores sólidos e de doença vascular.
BR0211905-6A 2001-08-22 2002-08-22 Dialdeìdos de rapamicina BR0211905A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31424901P 2001-08-22 2001-08-22
PCT/US2002/026717 WO2003018574A1 (en) 2001-08-22 2002-08-22 Rapamycin dialdehydes

Publications (1)

Publication Number Publication Date
BR0211905A true BR0211905A (pt) 2004-09-21

Family

ID=23219195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211905-6A BR0211905A (pt) 2001-08-22 2002-08-22 Dialdeìdos de rapamicina

Country Status (8)

Country Link
US (1) US6680330B2 (pt)
EP (1) EP1419153A1 (pt)
JP (1) JP2005503395A (pt)
CN (1) CN1545512A (pt)
BR (1) BR0211905A (pt)
CA (1) CA2455311A1 (pt)
MX (1) MXPA04001523A (pt)
WO (1) WO2003018574A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
CN1310908C (zh) 2001-08-22 2007-04-18 惠氏公司 雷帕霉素29－烯醇
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2005319427B2 (en) 2004-12-20 2011-11-03 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
HN2005035605A (es) 2004-12-20 2010-08-05 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
CA2595766A1 (en) 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
MX2007010892A (es) * 2005-03-07 2007-12-05 Wyeth Corp Isomero de oxepano de 42-o-(2-hidroxi)etil-rapamicina.
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
KR20080018874A (ko) * 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
EP1931321B1 (en) * 2005-08-31 2018-12-26 Abraxis BioScience, LLC Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US20070142422A1 (en) * 2005-12-20 2007-06-21 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) * 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
JP2014533294A (ja) 2011-11-15 2014-12-11 ノバルティス アーゲー ホスホイノシチド３−キナーゼ阻害剤およびヤヌスキナーゼ２−シグナル伝達兼転写活性化因子５経路の調節剤の組合せ
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
CN103705925B (zh) 2012-09-29 2018-03-30 段磊 抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en) 2012-09-29 2017-09-05 Targeted Therapeutics, Llc Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
MX2015004757A (es) 2012-10-16 2015-07-17 Endocyte Inc Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos.
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB2247456A (en) * 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5621108A (en) * 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
CA2266039A1 (en) 1996-09-09 1998-03-12 Thomas Joseph Caggiano Alkylated rapamycin derivatives
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives

Also Published As

Publication number Publication date
WO2003018574A1 (en) 2003-03-06
EP1419153A1 (en) 2004-05-19
CN1545512A (zh) 2004-11-10
MXPA04001523A (es) 2004-05-31
CA2455311A1 (en) 2003-03-06
US6680330B2 (en) 2004-01-20
JP2005503395A (ja) 2005-02-03
US20030100577A1 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
BR0211905A (pt) Dialdeìdos de rapamicina
BR0211986A (pt) 29-enóis de rapamicina
LTPA2019521I1 (lt) Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
CL2013002895A1 (es) Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005).
BR0114390A (pt) éteres de 7-desmetilrapamicina
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
BR0114345A (pt) Hidroxiésteres de 7-desmetilrapamicina
ATE433447T1 (de) Pyrimiidinverbindungen
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
PT1401841E (pt) Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
ECSP055584A (es) Proceso para la preparación de fibrinógeno
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
ATE359279T1 (de) Moschus-geruchsstoffe
SE9901077D0 (sv) Novel use
WO2003082268A3 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
BRPI0412843A (pt) lactamas substituìdas e uso das mesmas como agentes anticáncer
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired